tbuckley/cabot-search huggingface dataset:
OC-004 Prediction of Clinical and Endoscopic Remission after Autologous Stem cell Transplantation in Treatment Refractory Crohn’s Disease: Pooled Results from the Astic Trial:
Authors: JO Lindsay, M Allez, M Clark, M Labopin, E Ricart, J Satsangi, G Rogler, M Rovira, D Farge, C Hawkey
Journal: Gut (2016)

<h3>Introduction</h3> The randomised controlled ASTIC trial compared autologous stem cell transplantation (HSCT) with conventional care in treatment refractory Crohn’s disease (CD). Although the trial failed its ambitious primary endpoint (clinical remission for &gt;3 months off all CD medication with no ulceration on imaging / endoscopy at 1 year) significant benefit was seen in individual components. Patients randomised to conventional care subsequently underwent HSCT. We report outcome for all patients 1 year after HSCT and identify factors that predict remission. <h3>Methods</h3> Patients with active CD who were refrctory biologics underwent cyclophosphamide mobilisation and were randomised to immediate (4 weeks) or delayed (52 weeks) HSCT. Clinical (CDAI), endoscopic (SES-CD), and quality of life scores were compared immediately prior to (baseline) and one year after HSCT. An adjudication panel blinded to allocation and visit reviewed radiology and endoscopy. <h3>Results</h3> 45 patients with successful mobilisation were randomised to early (n = 23) or delayed (n = 22) HSCT. Data from baseline and 1 year after HSCT were available for 40 patients. Compared to baseline, there were significant improvements at 1 year for CDAI, PRO2, quality of life (IBDQ, and EQ5D) and SES CD (see Table). Complete endoscopic regression (SES-CD score of 0 in all segments examined) occurred in 26%, with complete ulcer healing in 50% and partial healing (ulcers ≤5 mm in no more than 2 segments) in 82%. Clinical remission (CDAI &lt; 150) at one year occurred in 46% patients (39% in remission &gt;3 months off steroids). On univariate analysis baseline factors associated with steroid free clinical remission at 1 year include colonic localization (p = 0.006), inflammatory phenotype (p = 0.009), high SES-CD (p = 0.005). Age, CRP and early vs delayed HSCT were not significant. On multivariate analysis high baseline SES CD was associated with steroid free remission at year 1 (OR 1.21 95%CI 1.03–1.41; p = 0.017). <h3>Conclusion</h3> One year outcome in the largest reported cohort of patients undergoing HSCT for refractory Crohn’s disease shows a significant reduction in both clinical and endoscopic disease activity with an improvement in quality of life. Endoscopic severity at baseline predict outcome. <h3>Disclosure of Interest</h3> None Declared
Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) as first-line chemotherapy for patients (pts) with advanced ovarian cancer (AOC): Preliminary results
Authors: G. Deplanque, A. Goupil, M. Fabbro, E. Levy, O. Rixe, B. Benettaib, E. Cvitkovic
Journal: Journal of Clinical Oncology (2004)

5075 Background: Despite the introduction of paclitaxel/platinum combinations in first line treatment of AOC, a small proportion of patients fail to respond. This has been linked to genetic or epigenetic deficiency in activity in mismatch repair (MMR; MLH1, MSH2). OXA has activity in MMR deficient cells and the OXA/ P combination has been shown to be safe and highly active in pre-treated AOC pts (Faivre et al. Ann Oncol 10:1125, 1999). This motivated the present phase II study in first line AOC. Methods: AOC pts with histologically proven stage IIc or IIIa-c after maximal debulking surgery (microscopic disease or macroscopic disease ≤2 cm) performed 2–7 weeks before study treatment start, received 175 mg/m2 P, 3-hour intravenous infusion, followed by 130 mg/m2 OXA, 2-hour intravenous infusion, every 3 weeks, on an outpatient basis, without G-CSF. A maximum of 6 cycles were administered before evaluation by second look laparoscopy or laparotomy. Pts with positive histology after second look surgery could receive up to 2 further cycles; pts with pathological complete response received no further treatment. Results: Between Aug 2001 and Jan 2003, 17 pts were entered in 9 centres (49 planned), 14 eligible, 3 ineligible (2 colorectal cancer with peritoneal presentation, 1 pre-treated with OXA/cisplatin/P). Median age 59 years (range 40–68); Performance status 0/1/2: 10/3/1; histology serous: 11, other: 3; FIGO stage IIIb: 5, IIIc: 9; microscopic residual disease: 3, macroscopic: 11. Patients received a median of 6 cycles (6–8). Efficacy: Of 13 pts evaluable for pathological response, 8 had complete response (62%) and 5 stable disease. With a median follow-up of 14 months (6–24), only 2 pts with macroscopic residual disease progressed. Median PFS: 14 months (5–22), 9 out of 12 patients have an ongoing PFS >12 months. Safety (NCI-CTC; 91 cycles) % by pts: neutropenia grade (Gr) 3/4: 7%/14%; febrile neutropenia: 7%, reversible neurosensory toxicity (OXA specific scale) ≥Gr2: 21%. Conclusion: The OXA/P combination shows high antitumor activity and a safe toxicity profile in first-line treatment for AOC. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration MGI Pharma, Inc. Sanofi
PULMONARY MONILIASIS
Authors: HENRY J. BAKST
Journal: JAMA (1934)

Three cases of pulmonary moniliasis came under observation in the Fifth Medical Service of the Boston City Hospital during November 1932. One was an infection secondary to pulmonary tuberculosis, the other two were primary infections. Because of the confusing symptomatology, the excellent results obtained with treatment and the sparseness of cases in American literature, it is believed that this report is warranted. Castellani's<sup>1</sup>early description of bronchomoniliasis was that of a disease closely simulating the clinical picture of pulmonary tuberculosis. Subsequent papers by various authors, however, described several other clinical manifestations of monilia infections of the lungs and bronchi. In addition to the often stressed resemblance to pulmonary tuberculosis,<sup>2</sup>also tracheobronchitis,<sup>3</sup>lobar pneumonia,<sup>4</sup>bronchopneumonia<sup>5</sup>and bronchial asthma<sup>6</sup>have been reported as the result of monilia infections of the respiratory organs. Although Castellani first focused attention on the fact that monilia may be the primary
Assessment of safety and feasibility of HIV protease inhibitors (PI) as antiangiogenic agents in the treatment of advanced nasopharyngeal carcinoma (NPC)
Authors: C. Simonelli, E. Vaccher, F. Martellotta, R. Tedeschi, E. Salvi, C. Sgadari, P. Monini, B. Ensoli, U. Tirelli
Journal: Journal of Clinical Oncology (2004)

3121 Background: HIV-PI inhibit the conversion of the active form of metalloproteinase-2 (MMP-2), thus preventing activation of proteases necessary for angiogenesis. In NPC, MMPs and VEGF are overexposed and their expression correlates with a poor prognosis. Methods: Since January 2002, we started the compassionate use of Indinavir for extensively pretreated pts. The aims of the study were to evaluate: feasibility and safety, serum and/or plasma level of the “anti-angiogenic surrogate markers” (MMP-2, MMP-3, MMP-9, VEGF and β FGF). Pts refractory to first-line, second-line conventional or to high dose chemotherapy (CT) plus ASCT and radiotherapy (RT) and pts who could not receive any intensive CT or RT were allowed to receive Indinavir, 800 mg tid po. alone or with concomitant Carboplatin (AUC 5) every 21 days. Toxicity according to WHO scale and biochemical tests for the “surrogate markers” were performed every 4, 8 weeks. Results: Six pts were enrolled. Five pts received therapy for a median time of 28 wks. One pt withdrew the informed consent after few days. Two pts received Indinavir alone for 16 and 15 weeks then continued Indinavir and Carboplatin for other 12 and 13 weeks. Three pts received Indinavir plus Carboplatin for the whole period. In 4 pts we observed nausea G1, only 1 pt interrupted Indinavir because of nausea G2. We did not observe any occurrence of kidney stones, hyperglycemia or increased level of bilirubin, elevate levels of transaminases. On the contrary, 2 pts showed lipodistrofy (buffalo bump) after 10 and 20 weeks, but cholesterol level was increased above the normal value only in 1 pt, while tryglicerides were normal in all pts. During the concomitant treatment with Carboplatin we observed only 1 G2 anaemia and 1 G1 leucopenia. The surrogate markers were measured in all pts and the results will be discussed in detail at the meeting. Conclusions: Treatment with Indinavir is feasible in pts with advanced NPC and does not increase toxicity due to concomitant use of Carboplatin. The development of lypodistrophy must be taken in account even if it is not a limiting-treatment toxicity in this setting. No significant financial relationships to disclose.
Permanent alopecia from pressure of a head strap
Authors: T. P. Gormley
Journal: JAMA (1967)

Postoperative (pressure) alopecia has previously been described as a reversible complication of prolonged anesthesia.<sup>1,2</sup>This presentation calls attention to permanent alopecia caused by pressure from a head strap used to hold the anesthetic mask to the face. <h3>Report of a Case</h3> A 4-year-olg boy was seen in the dermatology clinic for evaluation of hair loss of two weeks' duration. He had an operation (61/2 hours of anesthesia) 30 days previously for correction of bilateral traumatic deformities of the lower extremities, sustained in an automobile accident six months earlier. His health was otherwise excellent. The hair loss was not associated with pain, swelling, or exudation. Examination of the scalp revealed diffuse, moderately heavy, dirty-white seborrheic scaling of the entire scalp. Extending transversely across the supraoccipital portion of the scalp was a linear band, measuring 14 × 2 cm, of almost total hair loss. The few remaining hairs were easily epilated
Évaluation des pratiques professionnelles en endoscopie: Etude multicentrique de faisabilité d'une méthode simple et reproductible d'évaluation de la qualité de la coloscopie dans des structures privées et publiques
Authors: R Coriat, A Lecler, C Cassaz, H Roche, P Podevin, B Mesnard, O Berretta, C Nizou, D Sautereau, M Bouygues, M Gaudric, C Brezault, U Chaput, D Lamarque, F Prat, S Chaussade
Journal: Endoscopy (2009)

Introduction: L'EPP est une obligation légale et une nécessité dans le domaine de l'endoscopie digestive. Cette EPP doit évaluer l'ensemble des procédures rentrant en jeu avant, pendant et après l'acte. Une méthode simple et reproductible d'EPP a été développée afin d'évaluer la qualité de la coloscopie [1]. Le but de ce travail prospectif a été d'évaluer la faisabilité de cette méthode dans des centres d'endoscopie de CHU, de CHG, de PS-PH et dans des cliniques privées.
Errors in Figure and Funding/Support Paragraph
Journal: JAMA Internal Medicine (2017)

Daniel S. Reuland, MD, MPH; Alison T. Brenner, PhD; Richard Hoffman, MD, MPH; Andrew McWilliams, MD, MPH; Robert L. Rhyne, MD; Christina Getrich, PhD; Hazel Tapp, PhD; Mark A. Weaver, PhD; Danelle Callan, MA; Laura Cubillos, MPH; Brisa Urquieta de Hernandez; Michael P. Pignone, MD, MPH
From the Surgeon General, US Public Health Service
Authors: Antonia C. Novello
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Discussions
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Psychoactive Drug Use and AIDS
Authors: Roger K. Hershline
Journal: JAMA (1990)

<h3>To the Editor.—</h3> The June 16 issue of<i>JAMA</i>presented a report from the Multicenter AIDS Cohort Study entitled "No Evidence for a Role of Alcohol or Other Psychoactive Drugs in Accelerating Immunodeficiency in HIV-1—Positive Individuals."1 In this study, results obtained from a questionnaire about, for the most part, illicit drug use were compared with laboratory test results of human immunodeficiency virus type 1 antibody testing and peripheral blood lymphocyte phenotyping. Apparently, there was no attempt to measure urine or plasma drug levels. Drug verification is common practice in most medical fields, eg, psychiatry, internal medicine, pediatrics, and emergency medicine, and in many employment environments and sporting endeavors. Although history taking is a valuable tool, no conclusion of this nature can be drawn without acceptable verification.
Unsuspected parotid tumors
Authors: H. M. Griffiths
Journal: JAMA (1970)

During a recent six-year period, 33 patients with parotid tumors, 15 of which were malignant, were treated at the Indiana University Medical Center, Indianapolis. Eight patients presented with a history of prior minor surgical procedures, and among these, four had tumors which were malignant. Once a logical index of suspicion is established, errors of this type in the initial management of these lesions can be avoided. A brief resume of eight cases is presented.
Therapy of acute hepatitis C
Authors: Alfredo Alberti, Silvia Boccato, Alessandro Vario, Luisa Benvegnù
Journal: Hepatology (2002)

Acute hepatitis C has a high propensity to become chronic, which provides the rationale for treating patients with acute disease attempting to prevent chronicity. Almost all published studies on therapy of acute hepatitis C have been small in size, uncontrolled, and highly heterogeneous as to patient features, dose and duration of treatment, follow-up evaluation, and criteria used to define efficacy and safety. The published studies on treatment of acute hepatitis C have used standard alfa or beta interferon monotherapy: none have evaluated combination therapy of interferon and ribavirin or peginterferon. Several meta-analyses of published studies have concluded that initiation of interferon monotherapy during the acute phase of hepatitis C virus (HCV) infection significantly reduces (by 30% to 40%) evolution to chronic hepatitis. The tolerability of interferon in acute hepatitis C has been excellent, even in symptomatic and icteric patients; the side effects and adverse events being similar in type and frequency to those seen when treating chronic cases. Thus, currently available data support treatment of patients with acute hepatitis C, but data are insufficient to draw firm conclusions about which patients to treat, when therapy should be started, or what regimen is optimal. Future studies of adequate size and design should focus on efficacy and tolerability of peginterferons and whether therapy should be started immediately after diagnosis or delayed for 2 to 4 months to avoid treatment of patients who spontaneously recover. (Hepatology 2002;36:S195-S200).
COMPLICATIONS OF CONNECTIVE-TISSUE DISEASES
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Correction to the Research Article Titled: "Intranasal Antibody Gene Transfer in Mice and Ferrets Elicits Broad Protection Against Pandemic Influenza" by M. P. Limberis, V. S. Adam, G. Wong, J. Gren, D. Kobasa, T. M. Ross, G. P. Koblinger, A. Tretiakova, J. M. Wilson
Journal: Science Translational Medicine (2013)
Human Physiology
Authors: Thomas B. Calhoon
Journal: JAMA (1971)

This is an introductory text, compatible with the current trend towards more condensed exposure to basic sciences. Indeed, the book has the advantage that it can "be read and comprehended in less than one school year." Single authored, it has the continuity of thought, style, and approach which students find of great value. Unfortunately, one often has to trade off the virtue of continuity for unevenness of coverage. While most sections of the book are up to date, some fall below the level that one would have anticipated. There are several strong points in the text. First, Dr. Shepard has a superb ability to express organ system regulation into very excellent flow diagrams. There is an unusual number of these scattered throughout the text in strategic places. Despite the relatively small size of the book, the information content is very dense. Shepard packs a large number of pearls into a
The serum alkaline phosphatase
Authors: M. M. Karl
Journal: JAMA (1968)

The alkaline phosphatases constitute a large group of enzymes of low specificity that are involved in the hydrolysis of phosphate monoesters at a pH of about 9. They also play important roles in the transport of sugar and phosphate in the intestinal mucosa, kidney tubule, placenta, and bones. At the cellular level, they demonstrate activity against a wide variety of substrates but appear to be metabolically inert in the serum. Tissues that demonstrate the highest alkaline phosphatase activity include osteoblasts, bile canaliculi, intestinal mucosa, proximal convoluted tubules, and placenta. Alkaline phosphatase is present in serum, urine, feces, lymph, sweat, and breast milk. Large amounts are present in bile but whether the biliary tract represents the major mode of excretion still remains a matter of dispute. The serum alkaline phosphatase may originate then from bone, intestine, placenta, and the hepatobiliary system. Two possible mechanisms have been proposed to explain the elevated
ASSOCIATION NOTES.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New Drug Therapy Replaces Surgery In Some Dissecting Aortic Aneurysms
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum: Vol. 65, No. 20
Authors: Nina Ahmad, New York
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

In the MMWR report, "Possible Zika Virus Infection Among Pregnant Women - United States and Territories, May 2016," the following persons should be included in the Zika and Pregnancy Working Group: "Nina Ahmad, New York State Department of Health; Jennifer White, New York State Department of Health."